Company to add novel technology cleared for use in peripheral vasculature to interventional oncology and embolization portfolio MARLBOROUGH, Mass., Aug. 15, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel Embolic Material (GEM™) technology used for embolization of blood […]
Other News
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2022. “The Bellerophon team continues […]
Aerovate Therapeutics Announces Second Quarter 2022 Financial Results
WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended June 30, 2022, and recent business highlights. Recent Highlights Progress Continued […]
Heart Health Innovator Cleerly Appoints Joseph Jasser, MD, as Chief of Value Based Care
Hire follows Cleerly’s $223 million Series C and furthers value-based care business strategy NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced it has appointed Joseph “Joe” Jasser, MD, as chief of value based care. In this role, Dr. Jasser will be responsible for […]
Acutus Medical Reports Second Quarter 2022 Financial Results
CARLSBAD, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2022. Recent Updates: Reported revenue of $4.1 million in the […]
Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ended June 30, 2022 and provided key business updates. “Since announcing the positive topline results from […]
Vascular experts establish Appropriate Use of Intravascular Ultrasound (IVUS) in peripheral interventions
August 12, 2022 First-ever global consensus guidance published in the Journal of the American College of Cardiology: Cardiovascular Interventions Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions The results come ahead of the multi-society roundtable sponsored by SCAI on peripheral IVUS […]
Humacyte Second Quarter 2022 Financial Results and Business Update
— Human Acellular Vessels™ (HAVs™) successfully implanted in wounded Ukrainian citizens and reported to be functioning, saving limbs – — Hosted key opinion leader (KOL) webinar on HAV in the treatment of vascular trauma, featuring Ernest E. Moore, M.D and Gregory A. Magee, M.D. – — Strengthened Board of Directors with appointment […]
TridentCare Appoints Industry Veteran Daniel C. ‘Dan’ Buning as Chief Executive Officer
SPARKS, Md., Aug. 12, 2022 (GLOBE NEWSWIRE) — TridentCare, a national leader of portable diagnostic services, announced the appointment of Daniel C. “Dan” Buning as Chief Executive Officer and member of the Board of Directors. Buning has had a distinguished career both in the military and private industry where he […]
Neovasc Announces Second Quarter Financial Results and Provides Corporate Update
VANCOUVER and MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Generated revenues of $818,000, a quarterly record and a year-over-year increase of 29% over the second quarter […]



